| Title: |
Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison |
| Authors: |
Palandri F.; Kapetanakis V.; Dobi B.; Breccia M.; Palumbo G. A.; Abruzzese E.; Bonifacio M.; Tiribelli M.; Elli E. M.; Morsia E.; Branzanti F.; Ellis C. E.; Ballew N.; Liu T.; Phiri K.; Sen Nikitas F.; Zhang S.; Patnaik D. |
| Contributors: |
Palandri, F.; Kapetanakis, V.; Dobi, B.; Breccia, M.; Palumbo, G. A.; Abruzzese, E.; Bonifacio, M.; Tiribelli, M.; Elli, E. M.; Morsia, E.; Branzanti, F.; Ellis, C. E.; Ballew, N.; Liu, T.; Phiri, K.; Sen Nikitas, F.; Zhang, S.; Patnaik, D. |
| Publication Year: |
2026 |
| Collection: |
Università degli Studi di Udine: CINECA IRIS |
| Subject Terms: |
2L; Anemia; Best available therapy (BAT); Matching-adjusting indirect comparison (MAIC); Momelotinib; Myelofibrosis |
| Description: |
The Janus kinase (JAK) inhibitor ruxolitinib is a standard first-line therapy for patients with symptomatic and/or intermediate- to high-risk myelofibrosis (MF). However, the majority of patients discontinue ruxolitinib within 5 years of initiation, mainly due to lack or loss of response and/or therapy-related cytopenias. Additional treatments are needed to improve long-term outcomes, including overall survival (OS). Momelotinib, a JAK1/JAK2/activin A receptor type 1 inhibitor, has demonstrated benefits in reducing anemia and improving symptoms and spleen size in 3 phase 3 trials of patients with intermediate- to high-risk MF (SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM). These studies also provide data on patients who received momelotinib after discontinuing ruxolitinib. In the absence of long-term head-to-head comparisons of momelotinib and other treatments after discontinuation of ruxolitinib, the present study compared OS in patients with ruxolitinib-experienced MF from the momelotinib phase 3 trials vs. those treated with best available therapy (BAT) after ruxolitinib from the RUX-MF retrospective real-world study. The comparison was performed using an unanchored matching-adjusted indirect comparison (MAIC). Additionally, an MAIC of OS was conducted in an anemic subgroup (hemoglobin < 10 g/dL). After adjustment for cross-trial differences, the MAIC results showed a favorable trend for momelotinib vs. BAT, both in the overall population and in the anemic subgroup, with hazard ratios < 1 across all analytical scenarios and all population-matching models with an effective sample size of ≥ 20. This study is a key addition to current evidence surrounding OS post ruxolitinib and highlights the benefit of momelotinib in this setting. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/wos/WOS:001697041500001; volume:105; issue:4; firstpage:133; journal:ANNALS OF HEMATOLOGY; https://hdl.handle.net/11390/1325004 |
| DOI: |
10.1007/s00277-026-06873-w |
| Availability: |
https://hdl.handle.net/11390/1325004; https://doi.org/10.1007/s00277-026-06873-w |
| Rights: |
info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Accession Number: |
edsbas.7F9FC4CD |
| Database: |
BASE |